


CLINICAL OUTCOMES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY IN SMALL CELL LUNG CANCER

Tokhtasinov Nurmukhammadjon Akhmadjon Ugli
Fergana Central Asian Medical University (CAMU), Resident of Radiology Department, Fergana, Uzbekistan
Sulaymanov Dilmurod Abdullayevich
Head of the Department of Oncology and Medical Radiology, Fergana CAMU, PhD, Associate Professor
ORCID: 0008-0009-7314-7712

Abstract

Small cell lung cancer (SCLC) is one of the most aggressive and rapidly progressing forms of lung malignancy. It accounts for approximately 10–15% of all lung cancer cases worldwide and is characterized by rapid tumor growth, early metastatic spread, high proliferative activity, and poor long-term prognosis. Despite significant advances in cancer therapy, SCLC remains associated with high mortality rates and limited survival outcomes. Platinum-based chemotherapy has remained the cornerstone of first-line treatment for several decades, with cisplatin or carboplatin combined with etoposide representing the standard therapeutic regimen. This review evaluates the clinical outcomes, efficacy, and toxicity profile of platinum-based first-line chemotherapy in patients with SCLC. Data from international clinical guidelines, randomized clinical trials, and recent scientific publications were analyzed. Treatment response rates, overall survival, progression-free survival, and treatment-related adverse events were assessed. The findings indicate that platinum-based chemotherapy achieves high initial response rates ranging from 60% to 80%, with complete responses observed in approximately 20–30% of patients. However, despite favorable initial

responses, most patients eventually experience disease recurrence due to the development of therapeutic resistance. Hematological toxicities, including neutropenia, anemia, and thrombocytopenia, as well as non-hematological toxicities such as nephrotoxicity, neuropathy, nausea, and vomiting, remain significant clinical challenges. Recent incorporation of immune checkpoint inhibitors into first-line treatment regimens has demonstrated improvements in overall survival and disease control. Personalized treatment strategies, early toxicity management, and advanced imaging techniques may further improve clinical outcomes and quality of life for patients with SCLC.

Keywords: small cell lung cancer, platinum-based chemotherapy, cisplatin, carboplatin, etoposide, treatment outcomes, toxicity, immunotherapy.

Introduction

Lung cancer remains one of the leading causes of cancer-related mortality worldwide. According to global cancer statistics, millions of new cases are diagnosed annually, and lung cancer continues to account for a substantial proportion of cancer deaths. Among various histological subtypes, small cell lung cancer (SCLC) is considered one of the most aggressive forms due to its rapid growth rate, early metastatic potential, and high recurrence rate.

SCLC originates from neuroendocrine cells of the bronchial epithelium and is strongly associated with tobacco smoking. More than 90% of patients diagnosed with SCLC have a history of smoking, highlighting the critical role of tobacco exposure in disease development. Carcinogenic compounds present in cigarette smoke induce genetic mutations that contribute to malignant transformation. Mutations involving tumor suppressor genes such as TP53 and RB1 are frequently observed in SCLC and play a fundamental role in tumor progression.

One of the distinguishing characteristics of SCLC is its exceptionally rapid doubling time and high proliferative index. Consequently, the disease often spreads beyond the primary tumor site before clinical symptoms become apparent. At the time of diagnosis, the majority of patients already present with extensive-stage disease involving distant metastases to the liver, brain, bones, adrenal glands, or lymph nodes. This advanced presentation significantly limits the effectiveness of surgical intervention and emphasizes the importance of systemic treatment approaches.

Clinically, patients with SCLC commonly present with persistent cough, chest pain, dyspnea, hemoptysis, weight loss, fatigue, and decreased appetite. In advanced stages, neurological symptoms may develop due to brain metastases. Additionally,

paraneoplastic syndromes such as syndrome of inappropriate antidiuretic hormone secretion (SIADH) and Cushing syndrome may occur due to the neuroendocrine nature of the tumor.

For decades, platinum-based chemotherapy has served as the standard first-line treatment for SCLC. The combination of cisplatin or carboplatin with etoposide has demonstrated substantial antitumor activity and remains the preferred regimen in both limited-stage and extensive-stage disease. Although response rates are generally high, recurrence is almost inevitable in most patients, resulting in poor long-term survival outcomes.

Recent advances in immunotherapy have introduced new treatment opportunities for patients with SCLC. Immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1) have shown promising results when combined with chemotherapy. Nevertheless, platinum-based chemotherapy remains the foundation of treatment and continues to play a central role in disease management.

The purpose of this review is to evaluate the clinical efficacy, survival outcomes, and toxicity profile of platinum-based first-line chemotherapy in patients with small cell lung cancer.

Materials and Methods

This study was conducted as a narrative literature review based on published international guidelines, randomized controlled trials, systematic reviews, and meta-analyses related to the treatment of SCLC.

Scientific articles published in peer-reviewed journals were analyzed to evaluate treatment efficacy, survival outcomes, and adverse effects associated with platinum-based chemotherapy. Clinical recommendations from major oncology organizations, including the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and American Society of Clinical Oncology (ASCO), were reviewed.

Particular attention was given to studies comparing cisplatin-etoposide and carboplatin-etoposide regimens. Additionally, research investigating the integration of immunotherapy into first-line treatment protocols was assessed. Data regarding objective response rates, progression-free survival, overall survival, toxicity patterns, and radiological assessment methods were collected and synthesized.

Results and Discussion

Platinum-Based Chemotherapy as Standard First-Line Treatment

Platinum-based chemotherapy has remained the primary treatment strategy for SCLC for more than three decades. Cisplatin and carboplatin exert their antitumor effects through DNA cross-linking, leading to inhibition of DNA replication and induction of apoptosis in rapidly dividing tumor cells. Etoposide enhances cytotoxic activity by inhibiting topoisomerase II, resulting in DNA strand breaks.

The standard treatment protocol generally consists of four to six cycles administered every 21 days. In limited-stage disease, chemotherapy is often combined with thoracic radiotherapy, whereas extensive-stage disease is primarily treated with systemic chemotherapy.

Clinical Efficacy

Numerous clinical trials have demonstrated significant efficacy of platinum-based chemotherapy in SCLC. Objective response rates range from 60% to 80%, making SCLC one of the most chemotherapy-sensitive solid tumors. Complete responses are observed in approximately 20–30% of patients, particularly those diagnosed at earlier stages.

Patients with limited-stage disease generally experience more favorable outcomes than those with extensive-stage disease. Median overall survival ranges from 15 to 20 months in limited-stage SCLC, whereas extensive-stage disease is associated with median survival of 8 to 13 months. Five-year survival rates remain relatively low, highlighting the aggressive biological behavior of the disease.

Despite high initial response rates, disease recurrence remains a major challenge. Most patients experience relapse within 6–12 months after completion of therapy. Tumor resistance to chemotherapy develops rapidly, limiting the effectiveness of subsequent treatment lines.

Role of Immunotherapy

Recent clinical studies have transformed the treatment landscape of SCLC through the incorporation of immunotherapy. Immune checkpoint inhibitors such as atezolizumab and durvalumab have demonstrated improved survival when combined with platinum-etoposide chemotherapy.

These agents block PD-L1-mediated immune suppression, thereby enhancing antitumor immune responses. Clinical trials such as IMpower133 and CASPIAN reported statistically significant improvements in overall survival compared with chemotherapy alone. Although the survival benefit remains modest, immunotherapy represents a meaningful advancement in the management of extensive-stage SCLC.

Hematological Toxicity

Treatment-related toxicity remains one of the principal limitations of platinum-based chemotherapy. Hematological adverse events are particularly common and may require dose modifications or treatment delays.

Neutropenia is the most frequently observed hematological toxicity and can significantly increase the risk of severe infections. Febrile neutropenia represents a potentially life-threatening complication requiring prompt medical intervention. Anemia and thrombocytopenia are also frequently encountered and may negatively affect patient quality of life.

The use of granulocyte colony-stimulating factors (G-CSF) has significantly reduced the incidence and severity of chemotherapy-induced neutropenia. Regular monitoring of blood counts remains essential throughout treatment.

Non-Hematological Toxicity

Non-hematological adverse events also contribute substantially to treatment burden. Cisplatin is associated with significant nephrotoxicity, ototoxicity, electrolyte disturbances, and peripheral neuropathy. Adequate hydration protocols and renal function monitoring are therefore critical components of treatment.

Nausea and vomiting remain among the most distressing side effects for patients. The introduction of modern antiemetic medications has significantly improved symptom control and treatment tolerability.

Carboplatin generally exhibits lower nephrotoxicity and neurotoxicity than cisplatin but is associated with increased hematological toxicity. Consequently, treatment selection should be individualized according to patient age, performance status, comorbidities, and organ function.

Radiological Monitoring

Radiological imaging plays a pivotal role in evaluating treatment response and disease progression. Computed tomography (CT) remains the primary imaging modality used during follow-up. Magnetic resonance imaging (MRI) is particularly valuable for detecting brain metastases, while positron emission tomography/computed tomography (PET/CT) provides comprehensive assessment of metabolic tumor activity.

Response evaluation is commonly performed according to RECIST criteria, which classify treatment outcomes as complete response, partial response, stable disease, or progressive disease. Early identification of progression allows timely modification of therapeutic strategies.

Future Perspectives

Advances in molecular oncology continue to improve understanding of SCLC biology. Ongoing research focuses on targeted therapies, biomarker-driven treatment selection, antibody-drug conjugates, and novel immunotherapeutic approaches.

Artificial intelligence-assisted imaging analysis and genomic profiling may facilitate earlier diagnosis and more personalized treatment strategies in the future. These innovations hold promise for improving survival outcomes and reducing treatment-related toxicity.

Conclusion

Small cell lung cancer remains one of the most aggressive malignancies encountered in clinical oncology. Platinum-based first-line chemotherapy continues to represent the standard of care due to its high response rates and proven clinical efficacy. Cisplatin or carboplatin combined with etoposide provides substantial tumor regression in the majority of patients and remains the foundation of treatment in both limited-stage and extensive-stage disease.

However, treatment success is limited by frequent disease recurrence and significant toxicity. Hematological and non-hematological adverse effects require careful monitoring and supportive management. The integration of immune checkpoint inhibitors into first-line treatment regimens has improved survival outcomes and represents a significant advancement in the field.

Future progress in molecular diagnostics, targeted therapies, personalized medicine, and immunotherapy is expected to further enhance clinical outcomes for patients with SCLC. Continued research is essential to overcome therapeutic resistance and achieve long-term disease control in this challenging malignancy.

References

1. Horn L., Mansfield A.S., Szczęsna A., Havel L., Krzakowski M., Hochmair M.J., et al. (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379(23), 2220–2229.

2. Paz-Ares L., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., et al. (2019). Durvalumab plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet, 394(10212), 1929–1939.

3. Rudin C.M., Brambilla E., Faivre-Finn C., Sage J. (2021). Small-Cell Lung Cancer. Nature Reviews Disease Primers, 7(1), 3.

4. Kalemkerian G.P., Schneider B.J. (2024). Advances in Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 38(2), 205–221.

5. National Comprehensive Cancer Network (NCCN). (2025). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2025.

6. Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J.R., Bharat A., et al. (2024). Small Cell Lung Cancer, Version 1.2024, NCCN Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network, 22(1), 1–45.

7. Früh M., De Ruysscher D., Popat S., Crinò L., Peters S., Felip E. (2013). Small-Cell Lung Cancer (SCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 24(Suppl. 6), vi99–vi105.

8. van Meerbeeck J.P., Fennell D.A., De Ruysscher D.K. (2011). Small-Cell Lung Cancer. Lancet, 378(9804), 1741–1755.

9. Byers L.A., Rudin C.M. (2015). Small Cell Lung Cancer: Where Do We Go from Here? Cancer, 121(5), 664–672.

10. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. (2006). Changing Epidemiology of Small-Cell Lung Cancer in the United States over the Last 30 Years. Cancer, 107(5), 107–110.

11. Owonikoko T.K., Niu H., Nackaerts K., Csőszi T., Ostoros G., Mark Z., et al. (2021). Randomized Phase III Trial of Cisplatin and Etoposide versus Carboplatin and Etoposide in Small Cell Lung Cancer. Journal of Clinical Oncology, 39(15), 1672–1682.

12. Faivre-Finn C., Snee M., Ashcroft L., Appel W., Barlesi F., Bhatnagar A., et al. (2017). Concurrent Once-Daily versus Twice-Daily Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer (CONVERT): An Open-Label, Phase 3 Trial. Lancet Oncology, 18(8), 1116–1125.

13. Wang S., Zimmermann S., Parikh K., Mansfield A.S., Adjei A.A. (2019). Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clinic Proceedings, 94(8), 1599–1622.

14. Sabari J.K., Lok B.H., Laird J.H., Poirier J.T., Rudin C.M. (2017). Unravelling the Biology of SCLC: Implications for Therapy. Nature Reviews Clinical Oncology, 14(9), 549–561.

15. Dingemans A.C., Früh M., Ardizzoni A., Besse B., Faivre-Finn C., Hendriks L.E., et al. (2021). Small-Cell Lung Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Annals of Oncology, 32(7), 839–853.